The efficacy observed with Acadra is of particular interest because there is a obvious unmet clinical want in individuals who become resistant to standard therapies and especially in those who have alterations in the p53 gene, said Dr. Clara Campas, who is responsible for the clinical development co-author and applications of the Acadra patent. Dr. Campas added, The drug has important synergic effects with various other chemotherapy agents including bortezomib in multiple myeloma and anti-CD20 monoclonal antibodies in mantle cell lymphoma. The benefit of Acadra and anti-CD20 antibodies as mixture agents is definitely that both are B-cell directed and independent of p53. The results of the Phase I/II study comes with an acceptable basic safety and tolerability profile in doses which induce reduction in the leukemic tumor burden.Surveillance System Surveillance for poliomyelitis is conducted through surveillance for instances of acute flaccid paralysis. Cases are reported by hospitals to their county CDC within 2 days once they have been identified. County-level CDC staff are in charge of case investigation, transportation and assortment of stool specimens, and follow-up. Two specimens, each weighing 5 g or more, are acquired from patients with severe flaccid paralysis within 14 days after the onset of paralysis, with the next specimen gathered at least a day after the first specimen.